HIGHMARK HEALTH OPTIONS

Updated: 04/2025
Approved: 04/2025

Request for Prior Authorization for Tepezza (teprotumumab-trbw)
Website Form – www.wv.highmarkhealthoptions.com
Submit request via: Fax - 1-833-547-2030.

All requests for Tepezza (teprotumumab-trbw) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Tepezza (teprotumumab-trbw) Prior Authorization Criteria:

For all requests for Tepezza (teprotumumab-trbw) all of the following criteria must be met:

- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- Must be prescribed by or in consultation with a specialist in ophthalmology or endocrinology

Coverage may be provided with a diagnosis of Thyroid Eye Disease (TED) and the following criteria is met:

- Must be euthyroid or have thyroxine and free triiodothyronine levels less than 50% above or below normal limits
- **Initial Duration of Approval:** Eight infusions
- **Reauthorization criteria**
    - Requests outside 8 total infusions require documentation of peer-reviewed compendia supporting the member's healthcare outcome will be improved by dosing beyond the FDA approved treatment duration.
- **Reauthorization Duration of approval:** up to 8 infusions (dependent on peer-reviewed compendia support provided)

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

HIGHMARK HEALTH OPTIONS

Updated: 04/2025
Approved: 04/2025

TEPEZZA (TEPROTUMUMAB-TRBW) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX: (833)-547-2030.**
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: 1-844-325-6251 Mon – Fri 8 am to 7 pm

PROVIDER INFORMATION

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	

Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? ☐ Yes ☐ No

Billing Information

This medication will be billed: ☐ at a pharmacy **OR** ☐ medically, JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:	ICD Code:

Is the member euthyroid or have thyroxine and free triiodothyronine levels less than 50% above or below normal limits? ☐ Yes ☐ No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature	Date